Bailard’s Stoke Therapeutics STOK Stock Holding History

Bailard’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-43,300	Closed	-$1.46M	–	760
2021 Q2	$1.46M	Buy	43,300 +29,200	+207%	+$1.03M	0.05%	239
2021 Q1	$548K	Hold	14,100	–	–	0.02%	374
2020 Q4	$873K	Buy	+14,100	New	+$646K	0.04%	234

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's STOK Position: Q3 2021 in Review

Bailard sold out of Stoke Therapeutics (STOK) in Q3 2021, closing a stake of 43,300 shares — an estimated $1.46M sold.

Bailard first reported a position in STOK in Q4 2020 and held it in 3 quarters. The position peaked at $1.46M in Q2 2021. 90 funds tracked by Wall St. Rank hold STOK as of Q3 2021.

Bailard reported no remaining Stoke Therapeutics position as of Q3 2021 after selling out during the quarter.
Bailard sold 43,300 Stoke Therapeutics shares in Q3 2021, an estimated $1.46M.
Bailard first reported a position in Stoke Therapeutics in Q4 2020 and held it in 3 quarters.
Bailard's Stoke Therapeutics position peaked at $1.46M in Q2 2021.
90 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.